Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

被引:2
|
作者
Han, Chenglong [1 ]
Robinson, Don W.
Hackett, Monica V.
Paramore, L. Clark
Fraeman, Kathy H.
Bala, Mohan V.
机构
[1] Centocor Inc, Malvern, PA 19355 USA
[2] United BioSource Corp, Medtap Inst, Bethesda, MD USA
关键词
rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; cardiovascular disease;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To compare the prevalence of cardiovascular diseases and their risk factors between patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) and control subjects. Methods. Data for patients continuously enrolled in an integrated outcomes database between January 1, 2001, and December 31, 2002, with International Classification of Diseases, 9th Revision codes of 714.x (RA), 696.0 (PsA), or 720.0 (AS) were evaluated in this cross-sectional comparative study. Control groups were established for each patient group (1:4 ratio) by matching on the basis of age, sex, geographic region, and length of time in plan. Age- and sex-adjusted prevalence of cardiovascular comorbidities and risk factors were calculated; the prevalence ratio of the comorbidities and risk factors for the patient groups compared with the control population were estimated. Use of selected cardiovascular medications was also compared between patient and control groups. Results. The RA, PsA, and AS cohorts comprised 28,208, 3066, and 1843 patients, respectively. The prevalence ratio of ischemic heart disease (1.5, 1.3, 1.2), atherosclerosis (1.9, 1.4, 1.5), peripheral vascular disease (2.4, 1.6, 1.6), congestive heart failure (2.0, 1.5, 1.8), cerebrovascular disease (1.6, 1.3, 1.7), type 11 diabetes (1.4, 1.5, 1.2), hyperlipidemia (1.2, 1.2, 1.2), and hypertension (1.3, 1.3, 1.3) were higher in patients than controls. For RA, PsA, and AS, use of angiotensin-converting enzyme inhibitors, calcium channel blockers, diuretics, nitrates/vasodilators, anticoagulants, and antihyperlipidemia agents was significantly higher in patients than controls. Conclusion. Cardiovascular diseases and their risk factors were more common in patients with RA, PsA, and AS than in matched controls.
引用
收藏
页码:2167 / 2172
页数:6
相关论文
共 50 条
  • [1] Co-occurrences of selected cardiovascular diseases and risk factors in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Han, CL
    Robinson, D
    Hackett, M
    Paramore, C
    Fraeman, K
    Bala, M
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S34 - S35
  • [2] Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden
    Landgren, Anton Jonatan
    Dehlin, Mats
    Jacobsson, Lennart
    Bergsten, Ulrika
    Klingberg, Eva
    [J]. RMD OPEN, 2021, 7 (02):
  • [3] Risk: Benefit Profile of Etanercept in Elderly Patients with Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis
    Roy Fleischmann
    Imran Iqbal
    [J]. Drugs & Aging, 2007, 24 : 239 - 254
  • [4] Risk: Benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis
    Fleischmann, Roy
    Iqbal, Imran
    [J]. DRUGS & AGING, 2007, 24 (03) : 239 - 254
  • [5] WHEN ATHEROSCLEROSIS IS ESTABLISHED, CARDIOVASCULAR BIOMARKERS ARE COMPARABLE IN PATIENTS WITH ANKYLOSING SPONDYLITIS, RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS
    Ikdahl, E.
    Rollefstad, S.
    Hisdal, J.
    Provan, S. A.
    Berg, I. J.
    Stranden, E.
    Kvien, T. K.
    Olsen, I. C.
    Semb, A. G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 952 - 953
  • [6] Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis
    McCarey, D.
    Sturrock, R. D.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S124 - S126
  • [7] ETANERCEPT RETENTION RATES IN PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS
    Dongen, C. V.
    Kneepkens, E.
    Vogelzang, E.
    l'Ami, M.
    Krieckaert, C.
    van der Horst, I.
    Voskuyl, A.
    Nurmohamed, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 1145 - 1145
  • [8] BIOLOGIC USE IN NHS PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Queen, Anton B.
    Siebert, Stefan
    [J]. RHEUMATOLOGY, 2016, 55 : 124 - 124
  • [9] Golimumab In the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
    Oldfield, Vicki
    Plosker, Greg L.
    [J]. BIODRUGS, 2009, 23 (02) : 125 - 135
  • [10] GolimumabIn the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
    Vicki Oldfield
    Greg L. Plosker
    [J]. BioDrugs, 2009, 23 : 125 - 135